However, post-market surveillance has identified rare cases, prompting the FDA to strengthen product labeling
If a consumer can buy Wegovy or Zepbound for $350 directly from the manufacturer, employers are right to ask: Why should our health plan pay more than an individual paying cash? This transparency sets the stage for employers to push for: Mid-cycle GLP-1 repricing or rebate true-ups Most-favored-net clauses guaranteeing parity with manufacturer DTC pricing Dose-specific caps to prevent runaway spend as members titrate upward Even without an immediate financial impact, this public price signal changes the tone of employer-PBM negotiations heading into 2026
While this drives impressive fat loss, it also makes consuming adequate protein through regular meals extremely challenging
Taken together, our results indicate that binding of one IGF1 molecule is sufficient to break the autoinhibited state of IGF1R, leading to receptor activation
Data Availability All data are presented in this manuscript or supplemental figure
Use of anti-CGRP monoclonal antibodies to treat headache in patients with idiopathic intracranial hypertension: a retrospective study (P10-2.006)
.png)
